Bayer HealthCare reports that the number of blood-clot-related deaths in Europe supersede the total number of deaths attributed HIV/AIDS, prostate cancer and breast cancer. This reflects the need for anticoagulants before, during, and after surgical procedures or while a patient is undergoing treatment for neurological disorders and cancer. This brings heparin, a widely used anticoagulant, into focus.
This anticoagulant has emerged as a market by and of itself in recent years. This can be seen in the findings of recent market research reports. According a report published by Transparency Market Research, the Europe Heparin market will post a compounded annual growth rate (CAGR) of 5.2% between 2014 and 2022, as it rises from its 2013 value of US$2,004.5 million to US$3,148.0 million in 2022.
Avail a Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4815
Heparin, which is released by blood basophils and mast cells, is a sulfated glycosaminoglycan. It is most commonly used during blood transfusion procedures, to treat clotting disorders, as well as during blood sampling. Here’s how heparin works: It renders added efficacy to anti-thrombin III, a naturally-occurring compound that thwarts the progress of activated clotting factors. As evidenced by recent studies, heparin also works against substances known to further angiogenesis.The heparin market, by product type, can be classed into low molecular weight heparin (LMWH), unfractionated heparin, and ultra-low molecular weight heparin. LMWH is poised for strongest growth in the near future because of its sheer versatility in application.
With Imports from China Restricted, Production of Heparin in Europe to Gain Impetus
The demand for heparin products has only moved upward with a growth in the incidences of renal disorders and a rise in coagulation among patients in Europe. Moreover, this scenario has been augmented with the fact that many European countries have imposed bans on the import of sub-standard heparin products from China. With the imports from China seeing a downslide, the manufacture of heparin products in Europe will catch on, helping the heparin market in Europe expand.
The Europe heparin market has not been able to reach its full potential because it was plagued by a demand-supply gap. This is also the reason companies in the heparin market in Europe had to resort to importing products. However, this issue is expected to be resolved as many slaughterhouse owners in Europe are now showing a willingness to foray into the heparin processing business. If this development plays out successfully, the demand-supply gap will no longer be a concern in the Europe heparin market. The overall demand for anti-coagulants is witnessing a rise in Europe, and this augurs well for the heparin market as well.
Restraints in the Form of Alternatives to Curtail Growth of Europe Heparin Market
Like most other naturally-occurring substances, heparin is also available in the synthetic version on the market. The synthetic version is relatively cheaper, which makes its uptake higher as compared to the biologically-sourced heparin products. Being an anticoagulant, Heparin also faces competition from other coagulants such as warfarin. This impedes the growth of the Europe heparin market to some extent. Moreover, companies in the heparin market will have to contend with other factors such as strict quality control practices that extend time-to-market.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.